Therefore, one way to prevent HSC activation and reduce hepatic fibrosis is to inhibit activated HSCs by stopping the TGF-β/Smad3 signaling pathway, which is considered a potential therapeutic target (14-16). This evidence concerns the gene TGFB1 and Hepatic fibrosis.